Johnson & Johnson and AstraZeneca resume vaccine trials


NEW YORK Johnson & Johnson and AstraZeneca have resumed trials of their experimental COVID-19 vaccine after regulatory approval, local media reported on Friday.

The United States Food and Drug Administration (FDA) has given the two companies the green light to continue their vaccine trials.

The FDA examined the diseases on subjects, which led to the studies being suspended and decided that the diseases were not from the COVID-19 vaccines.

“The restart of clinical trials around the world is excellent news because it allows us to continue our efforts to develop this vaccine to help defeat this terrible pandemic,” said Pascal Soriot, CEO of AstraZeneca.

On September 6, the US trials of AstraZeneca were suspended after a serious neurological disease discovered in a participant.

On October 12, Johnson & Johnson suspended its trials after a study participant fell ill.

* Writing by Gozde Bayar
The Anadolu Agency website contains only a portion of the stories available to subscribers of the AA News System (HAS), and in summary form. Please contact us for subscription options.


Please enter your comment!
Please enter your name here